XWELL shares skyrocketed over 300% to their highest level since January 2025 after announcing a $31.3 million private placement with American Ventures. The deal involves selling preferred shares and using proceeds to buy back notes and redeem warrants. The stock also surpassed its 200-day moving average for the first time in nearly four months.

Oddity Tech shares plummeted over 50% after forecasting a 30% revenue decline for Q1 2026. The company blamed algorithm changes at a major advertising partner for rising costs. Jefferies downgraded the stock to Hold and slashed its price target by 72% to $18, despite Q4 revenue beating expectations.

SoundHound AI shares gained after launching a new innovation hub in Bengaluru to bolster its AI agent ecosystem. The move targets India's rapidly growing tech sector. The new facility will enhance research and engineering efforts, joining existing global offices. This expansion underscores SoundHound's commitment to scaling its agentic AI technology worldwide.

Longeveron shares rose 7% after its investigational therapy, laromestrocel, showed positive results in a trial for age-related clinical frailty. The study found that intravenous administration improved physical condition after nine months compared to a placebo. The therapy utilises allogeneic stem cells and was tested on 148 ambulatory individuals.

British luxury carmaker Aston Martin confirmed on Wednesday it will cut a further 20% of its workforce, marking another round of job losses as annual profits fell short of expectations. The job losses total around 600, with Aston Martin employing around 3,000 people. The firm, which has been struggling for years, last month blamed US President Donald Trump's tariffs.

Intuitive Machines (LUNR) shares fell 16% after announcing a $175 million equity investment priced at $15.12 per share. The deal dilutes shareholders by about 9.7% but aims to fund higher-margin NASA and Golden Dome initiatives. Retail traders labelled the drop an overreaction as the company accelerates its space infrastructure expansion.

CASI Pharmaceuticals shares plummeted 64% to an all-time low after Nasdaq decided to delist the company for failing to meet listing requirements. Trading will be suspended on Thursday, and CASI does not plan to appeal. The company expects its shares to move to the over-the-counter market following the removal from Nasdaq.

Strategy has become the most shorted US large-cap stock, with roughly 14% of its market capitalisation sold short as of late January, according to Goldman Sachs data cited by the Financial Times. A year earlier, the company was not even among the top 50 most shorted names in that category.

Incannex Healthcare stock plummeted over 32% after the board approved a 1-for-30 reverse stock split effective February 26. The move is intended to help the company regain compliance with Nasdaq's minimum bid price requirements. The consolidation will reduce outstanding shares from 358.3 million to 11.94 million.

Enveric Biosciences shares gained over 4% after Gilgamesh Pharmaceuticals withdrew a challenge against the company's psilocybin patent. Enveric confirmed there are no remaining challenges against the patent, which covers new chemical versions for treating mental health disorders like depression and anxiety.